{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Metastatic clorectal cancer"],"disease":["Metastatic Clorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2624268"],"location":["Japan"],"study_start_month":["9"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Randomized Phase III Study of mFOLFOX7 or CAPOX plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (JCOG1018, RESPECT)","description":"Interventions: A: Fluoropyrimidine (5-FU/LVor capecitabine) + bevacizumab\nB: Fluoropyrimidine (5-FU/LV or capecitabine) + oxaliplatin + bevacizumab\nPrimary outcome(s): Progression-free survival\nStudy Design: Parallel Randomized","dates":{"creation":"2012-09-15"},"accession":"2624268","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000008866"]}}